Akeso, Inc. Annual Report 2025: Key Highlights, Investor Insights and Potential Price-Sensitive Developments

Executive Summary

Akeso, Inc. has released its Annual Report for the financial year ended December 31, 2025. The report provides a comprehensive overview of its financial performance, business activities, internal controls, corporate governance, and shareholder-related matters. Below are the key highlights and potential price-sensitive issues that investors and shareholders should pay close attention to.

Key Financial Highlights

• Losses Deepen: The company reported a consolidated loss attributable to owners of the parent of RMB 1,113 million for 2025, a significant increase from RMB 514 million in 2024. The basic and diluted loss per share grew to RMB 1.23 from RMB 0.60, reflecting widening losses. This could weigh on investor sentiment and share price.
• Quick Ratio Remains Strong: The quick ratio stood at 4.71, indicating robust liquidity and the ability to meet short-term obligations.
• Gearing Ratio Not Meaningful: Interest-bearing bank and other borrowings less cash and bank balances were negative, resulting in a non-meaningful gearing ratio. This signals the company holds more cash than debt, a positive for financial stability.
• Charitable Donations: Akeso made charitable donations of RMB 38.1 million, down slightly from RMB 41.8 million last year.

Capital Raising and Share Placements

• 2025 Share Placement: On September 4, 2025, Akeso issued 23,550,000 new shares at HK\$149.54 per share, raising net proceeds of approximately HK\$3,493 million. This placement represented 2.56% of the enlarged issued share capital and was done at a discount to market prices. The proceeds were earmarked for business development. Such a large placement might dilute existing shareholders and impact share price, but also strengthens the company’s cash position and ability to invest in growth.
• 2024 Placement: In October 2024, 31,700,000 shares were placed at HK\$61.28 per share, raising HK\$1,924 million net. Similar to the 2025 placement, this was conducted at a discount to market and expanded the shareholder base.

Business Performance and Risks

• Business Expansion and R&D: Akeso continues to invest heavily in research and development, with staff costs rising to RMB 1,423 million (up from RMB 950 million in 2024). The employee base grew to 3,761 from 3,035, reflecting scaling operations.
• Principal Risks: The report highlights several risks including the need for additional capital, potential delays in drug development, reliance on successful clinical results, intellectual property protection challenges, and risks related to collaborations. These could materially affect future performance and share value.
• Customer and Supplier Profile: Revenue dependence on the five largest customers fell to 25.2% (from 31.7%), indicating improved diversification. Purchases from the five largest suppliers increased to 26.4%.

Internal Controls and Compliance

• Enhanced Internal Controls: Following a non-timely announcement regarding a Supplemental Agreement, Akeso has strengthened its internal controls, including regular reviews, enhanced training for management and key staff, and improved coordination among departments to ensure compliance with the Hong Kong Listing Rules.
• Legal and Regulatory Compliance: The Group reports no material breaches or non-compliance during the year, which is positive for investor confidence.

Share Incentive Schemes and Options

• Termination of Pre-IPO RSU Scheme: The Pre-IPO RSU Scheme was terminated on June 30, 2024. Awards already granted remain valid, but no new awards will be granted under this scheme.
• 2021 RSU Scheme and Share Option Scheme: The company continues to operate the 2021 RSU Scheme and a Share Option Scheme, with well-defined eligibility, grant, and adjustment mechanisms. These schemes incentivize key personnel but may also lead to dilution if exercised.

Corporate Governance and Shareholder Matters

• Dividend Policy: Akeso has never declared or paid regular cash dividends and does not anticipate paying dividends in the foreseeable future due to accumulated losses. This is important for income-focused investors.
• Public Float Maintained: The company confirms compliance with public float requirements under the Listing Rules.
• No Controlling Shareholder: As of December 31, 2025, Akeso had no controlling shareholder, and no shares were pledged to secure company debts.
• No Debentures or Material Legal Proceedings: The Group did not issue any debentures and was not involved in any material legal proceedings during the year.

Audit and Assurance

• External Audit: Ernst & Young audited the 2025 financial statements, confirming that the company’s connected transactions complied with Board approval, pricing policies, transaction agreements, and annual caps.
• Audit Fees: Total audit and non-audit fees amounted to RMB 3,516,000.

Potential Price-Sensitive Issues for Shareholders

• Widening Losses: The deepening losses are likely to negatively impact investor sentiment. If this trend continues, it could exert downward pressure on share prices.
• Large Share Placements: The 2025 and 2024 share placements at discounts to market price may cause dilution and affect share value, though they also enhance cash reserves for future growth.
• Dividend Policy: The ongoing policy of not paying dividends may disappoint income-focused investors and limit upside potential for those seeking regular returns.
• Internal Control Improvements: The company’s remedial actions following compliance lapses are positive for governance but highlight previous weaknesses that investors should monitor.

Conclusion

Akeso, Inc.’s 2025 Annual Report reveals both opportunities and challenges facing the company. While it continues to invest in R&D and expand its business, the deepening losses, large share placements, and absence of dividends are key concerns for investors. Internal controls and compliance enhancements are steps in the right direction, but shareholders should monitor ongoing risks and the company’s path to profitability.

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities. Investors should conduct their own due diligence and consult with professional advisors before making any investment decisions. The information presented is based on the company’s published annual report and may be subject to change without notice.

View AKESO Historical chart here